Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
NCT ID: NCT00185315
Last Updated: 2010-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
71 participants
INTERVENTIONAL
2000-02-29
2005-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
NCT01894035
Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years
NCT00250640
Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years
NCT01389271
Efficacy of Ventavis Used in Real-life Setting.
NCT01355380
Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study
NCT01469169
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Ventavis (Iloprost, BAYQ6256)
Inhaled iloprost
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ventavis (Iloprost, BAYQ6256)
Inhaled iloprost
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Investigator judged iloprost aerosol therapy warranted as a suitable treatment for the respective patient
* Negative pregnancy test for females
Exclusion Criteria
18 Years
71 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bayer Schering Pharma AG
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brussels, , Belgium
Leuven, , Belgium
Clamart, , France
Grenoble, , France
Lille, , France
Reims, , France
Tours, , France
Bologna, BO, Italy
Montescano, Pavia, Italy
Pisa, PI, Italy
Amsterdam, , Netherlands
Warsaw, , Poland
Coimbra, , Portugal
Vila Nova de Gaia, , Portugal
Barcelona, Barcelona, Spain
Madrid, Madrid, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
303045
Identifier Type: -
Identifier Source: secondary_id
Follow-up 90419-300180
Identifier Type: -
Identifier Source: secondary_id
90570
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.